Protein may help detect early pancreatic cancer
the ONA take:
A protein encoded in the glypican-1 (GPC1) gene may allow for a non-invasive screening tool to detect early pancreatic cancer, according to a study published in Nature.
Raghu Kalluri, MD, PhD, and fellow researchers from The University of Texas MD Anderson Cancer Center examined GPC1-enriched exosomes (GPC1+ crExos) from the blood of patients with pancreatic cancer.
“GPC1+ crExos were detected in small amounts of serum from about 25 patients with pancreatic cancer with absolute specificity and sensitivity, importantly distinguishing patients with chronic pancreatitis from those with early- and late-stage pancreatic cancer,” said Dr. Kalluri.
They found that GPC1+ crExos levels were significantly lower in patients upon surgical removal of the tumor. Cancer exosomes, they concluded, can be isolated to provide cancer-specific information in addition to acting as a biomarker.
With routine screening through the use of MRIs or CT scans being “prohibitively expensive,” the study authors believe that GPC1+ crExos may be used as an effective detection tool in combination with imaging.
A protein encoded in the glypican-1 (GPC1) gene may allow for a non-invasive screening tool to detect early pancreatic cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|